Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019
These findings emphasize the variability in treatment efficacy following CDK4/6i therapy and underscore the importance of personalized treatment strategies. Further research is needed to optimize therapeutic sequences and improve patient outcomes in this setting.
Authors
- Fabio Canino (ORCID: https://orcid.org/0000-0002-1379-7667)
- Angela Toss (ORCID: https://orcid.org/0000-0002-1854-6701)
- Patrizia Vici (ORCID: https://orcid.org/0000-0001-7528-9783)
- E. Zattarin
- Luca I. Moscetti (ORCID: https://orcid.org/0000-0002-9108-4849)
- Monica Civallero (ORCID: https://orcid.org/0000-0001-8606-5806)
- Marco De Dominici (ORCID: https://orcid.org/0000-0002-1019-1715)
- E. Barbieri (ORCID: https://orcid.org/0000-0002-4980-3985)
- T. Arcuri
- Claudia Omarini
- F. Caggia
- G. Zoppoli
- Laura Cortesi (ORCID: https://orcid.org/0000-0001-8950-8561)
- Antonino Musolino (ORCID: https://orcid.org/0000-0002-7979-6261)
- Monica Barbolini (ORCID: https://orcid.org/0000-0001-6559-6747)
- Lucia Filomeno (ORCID: https://orcid.org/0000-0002-9867-9319)
- S. Natalizio
- Federico Piacentini (ORCID: https://orcid.org/0000-0001-8969-638X)
- Francesco Ravera (ORCID: https://orcid.org/0000-0003-3856-7910)
Institutions
- University of Modena and Reggio Emilia (IT)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Italian Oncology Group of Clinical Research (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- National Cancer Institute (MY)
- Tumori Foundation (US)
- Ospedale Policlinico San Martino (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100154
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00